239 related articles for article (PubMed ID: 24257566)
1. Magnetic resonance imaging/positron emission tomography provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration.
Vargas HA; Burger IA; Donati OF; Andikyan V; Lakhman Y; Goldman DA; Schöder H; Chi DS; Sala E; Hricak H
Int J Gynecol Cancer; 2013 Oct; 23(8):1512-9. PubMed ID: 24257566
[TBL] [Abstract][Full Text] [Related]
2. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.
Burger IA; Vargas HA; Donati OF; Andikyan V; Sala E; Gonen M; Goldman DA; Chi DS; Schöder H; Hricak H
Gynecol Oncol; 2013 Jun; 129(3):586-592. PubMed ID: 23369941
[TBL] [Abstract][Full Text] [Related]
3. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.
Donati OF; Lakhman Y; Sala E; Burger IA; Vargas HA; Goldman DA; Andikyan V; Park KJ; Chi DS; Hricak H
Eur Radiol; 2013 Oct; 23(10):2906-15. PubMed ID: 23652852
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
Husain A; Akhurst T; Larson S; Alektiar K; Barakat RR; Chi DS
Gynecol Oncol; 2007 Jul; 106(1):177-80. PubMed ID: 17477959
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
[TBL] [Abstract][Full Text] [Related]
6. Value of fusion of PET and MRI in the detection of intra-pelvic recurrence of gynecological tumor: comparison with 18F-FDG contrast-enhanced PET/CT and pelvic MRI.
Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Makihara N; Ebina Y; Yamada H; Takahashi S; Sugimura K
Ann Nucl Med; 2014 Jan; 28(1):25-32. PubMed ID: 24129541
[TBL] [Abstract][Full Text] [Related]
7. Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies.
Lakhman Y; Nougaret S; Miccò M; Scelzo C; Vargas HA; Sosa RE; Sutton EJ; Chi DS; Hricak H; Sala E
Radiographics; 2015; 35(4):1295-313. PubMed ID: 26172364
[TBL] [Abstract][Full Text] [Related]
8. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
[TBL] [Abstract][Full Text] [Related]
9. Comparison of
Sawicki LM; Kirchner J; Grueneisen J; Ruhlmann V; Aktas B; Schaarschmidt BM; Forsting M; Herrmann K; Antoch G; Umutlu L
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):622-629. PubMed ID: 29164299
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis: a comparison to whole-body magnetic resonance imaging alone.
Grueneisen J; Beiderwellen K; Heusch P; Gratz M; Schulze-Hagen A; Heubner M; Kinner S; Forsting M; Lauenstein T; Ruhlmann V; Umutlu L
Invest Radiol; 2014 Dec; 49(12):808-15. PubMed ID: 25010207
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer.
Park JY; Kim EN; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2008 Mar; 108(3):486-92. PubMed ID: 18201753
[TBL] [Abstract][Full Text] [Related]
12. Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer.
Sala E; Micco M; Burger IA; Yakar D; Kollmeier MA; Goldman DA; Gonen M; Park KJ; Abu-Rustum NR; Hricak H; Vargas HA
Int J Gynecol Cancer; 2015 Oct; 25(8):1461-7. PubMed ID: 26397068
[TBL] [Abstract][Full Text] [Related]
13. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and diagnostic performance of hybrid PET/MRI compared with PET/CT for gynecological malignancies: a prospective pilot study.
Schwartz M; Gavane SC; Bou-Ayache J; Kolev V; Zakashansky K; Prasad-Hayes M; Taouli B; Chuang L; Kostakoglu L
Abdom Radiol (NY); 2018 Dec; 43(12):3462-3467. PubMed ID: 29948057
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings.
Inubashiri E; Hata K; Kanenishi K; Shiota A; Ohno M; Yamamoto Y; Nishiyama Y; Ohkawa M; Hata T
J Obstet Gynaecol Res; 2009 Feb; 35(1):26-34. PubMed ID: 19215544
[TBL] [Abstract][Full Text] [Related]
17. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
18. Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT.
Grueneisen J; Schaarschmidt BM; Heubner M; Suntharalingam S; Milk I; Kinner S; Heubner A; Forsting M; Lauenstein T; Ruhlmann V; Umutlu L
Eur J Radiol; 2015 Nov; 84(11):2097-102. PubMed ID: 26321491
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of Computed Tomography for Preoperative Staging of Patients with Non-endometrioid Carcinomas of the Uterine Corpus.
Lakhman Y; Katz SS; Goldman DA; Yakar D; Vargas HA; Sosa RE; Miccò M; Soslow RA; Hricak H; Abu-Rustum NR; Sala E
Ann Surg Oncol; 2016 Apr; 23(4):1271-8. PubMed ID: 25665953
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer.
Vargas HA; Akin O; Schöder H; Olgac S; Dalbagni G; Hricak H; Bochner BH
Eur J Radiol; 2012 Dec; 81(12):4131-7. PubMed ID: 22858427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
